ライフサイエンスコーパス: treatment adherence

1 lifestyles, optimise medication, and improve treatment adherence.

2 re were no differences in service contact or treatment adherence.

3 ia that compromise quality of life and limit treatment adherence.

4 er treatment initiation among women or lower treatment adherence.

5 ex disparity in treatment initiation and not treatment adherence.

6 creasing rates of treatment, monitoring, and treatment adherence.

7 onal incentives contingent on abstinence and treatment adherence.

8 ing, willingness to adhere to treatment, and treatment adherence.

9 s, family, and friends was a facilitator for treatment adherence.

10 essing the ingestion of oral medications and treatment adherence.

11 easures that may prevent relapse and improve treatment adherence.

12 vels of psychosocial well-being and rates of treatment adherence.

13 only one tablet once-a-day, which increases treatment adherence.

14 Three studies added to the understanding of treatment adherence.

15 hanced by community-based social support for treatment adherence.

16 be an important consideration in maximizing treatment adherence.

17 , 0.88-3.89-borderline), partial/poor asthma treatment adherence (2.54, 0.97-6.67-borderline), and an

18 Because of inadequate clinical follow-up or treatment adherence, 2251 infants were included in the p

19 t inclusion, 20.9% of patients reported good treatment adherence, 72.0% minor nonadherence, and 7.1%

20 Treatment adherence, adverse effects, and effectiveness

21 We examine differences by education in treatment adherence among patients with two illnesses, d

22 epression in primary care resulted in better treatment adherence and better clinical outcomes at 4 an

23 therapy sessions holds promise for improving treatment adherence and completion among depressed patie

24 Patients were compared on treatment adherence and completion and on 1-year rehospi

25 ivational therapy intervention on outpatient treatment adherence and completion for patients with com

26 als, which had found greater improvements in treatment adherence and depressive symptoms at 4 and 7 m

27 Patient benefits, such as increased treatment adherence and enhanced adaptation, need to be

28 ntions for reducing incidence were improving treatment adherence and increasing testing frequency and

29 at 6 months and every 12 months, to monitor treatment adherence and minimize failure, and will publi

30 e target for intervention aimed at improving treatment adherence and outcomes.

31 However, the rates of treatment adherence and premature discontinuation of tre

32 ying anorexia and weight loss that may limit treatment adherence and reduce patient quality of life.

33 combinations (FDC) has been shown to improve treatment adherence and risk factor control.

34 ve diagnoses, together with an evaluation of treatment adherence and side-effects from medications.

35 mental disorders, technologies for promoting treatment adherence and supporting recovery, online self

36 It has been suggested that SDM can improve treatment adherence and that ignoring patients' personal

37 l factors), pathophysiology, and response to treatments (adherence and relapse) of drug dependence vs

38 ms, regular patient follow-up, monitoring of treatment adherence, and a prominent role for the mental

39 including impaired quality of life, reduced treatment adherence, and increased disease-related morbi

40 decreased cognition leading to problems with treatment adherence, and the role of screening and basic

41 ioural factors including self-management and treatment adherence, and therefore, there is a reasonabl

42 energy, the rewards associated with optimal treatment adherence are worth the effort.

43 py require support to insure a high level of treatment adherence, but the evidence about effective in

44 Treatment adherence can be measured by use of a variety

45 Patients receiving TTFC maintained better treatment adherence compared with patients receiving TRA

46 In the binocular group, treatment adherence data from the iPad device indicated

47 Instruments that assessed attachment, treatment adherence, depression, diabetes severity, pati

48 examining the effect of patient dropout and treatment adherence did not alter the results.

49 portional hazards models adjusted for recent treatment adherence estimated the relative risk of virol

50 , treatment completion, case management, and treatment adherence for tuberculosis.

51 er quality that is a source of risk and high treatment adherence (>90% of water consumed is treated).

52 f virologic failure in the setting of recent treatment adherence (hazard ratio, 3.45 [95% confidence

53 e development of substance use disorders and treatment adherence in bipolar youth are necessary to im

54 ider communication is associated with poorer treatment adherence in patients with diabetes.

55 However, little is known about treatment adherence in teenage and young adult (TYA) pat

56 Factors that have been shown to affect treatment adherence in TYA patients include patient emot

57 he lack of interventional studies addressing treatment adherence in TYA patients with cancer, with on

58 enhance psychosocial well-being and increase treatment adherence in young adult patients with advance

59 ogist alliance, psychosocial well-being, and treatment adherence in young adults with advanced cancer

60 effectiveness and cost-effectiveness of HIV treatment adherence intervention strategies.

61 We conclude that treatment adherence is a key factor for a positive outco

62 urthermore, understanding predictors of poor treatment adherence is a necessary step toward developin

63 gain, leading to further morbidity and poor treatment adherence, is a common consequence of treatmen

64 e in important clinical outcomes, such as HF treatment adherence, is unclear.

65 were associated with improved HT control and treatment adherence, mainly evaluated in US settings.

66 ons, combined with the reality of suboptimal treatment adherence, make drug resistance a clinical and

67 Treatment adherence (medication possession ratio [MPR])

68 nclature, prevalence, origins, and effect on treatment adherence of TCS phobia in atopic dermatitis.

69 nse to binocular treatment was owing to poor treatment adherence or lack of treatment effect.

70 as a threshold to initiate investigations of treatment adherence or possible treatment failure.

71 tions to physicians and helped patients with treatment adherence over 24 months.

72 WC2031 could improve treatment adherence over twice-daily Vibramycin.

73 to evaluate the relationship between DFS and treatment adherence (persistence [duration] and complian

74 eened for coexisting psychosocial issues and treatment adherence problems.

75 on should be a priority if one is to improve treatment adherence, quality of life, and outcomes in tr

76 itive to the cost of protease inhibitors and treatment adherence rates.

77 After adjustment for treatment adherence, recurrent VTE was reduced by 42% (H

78 lower levels of psychosocial well-being and treatment adherence relative to patients with cancer in

79 eful in characterizing study populations, in treatment adherence research, and as a clinical and rese

80 Persistence was lower with treatment adherence (risk ratio, 0.4 [0.2 to 0.9]).

81 a treatment response of 50%, although better treatment adherence showed a higher response.

82 uberculosis drugs; and strategies to improve treatment adherence, such as directly observed therapy,

83 We assessed the effect of automated treatment adherence support delivered via mobile phone s

84 lly meaningful outcome indicators, including treatment adherence, symptom remission, and quality of l

85 testing, linkage to care, treatment uptake, treatment adherence, treatment completion, treatment out

86 Treatment adherence was good and few patients discontinu

87 Treatment adherence was monitored.

88 Treatment adherence was similar in African American and

89 tly favored study patients, but IL28B GT and treatment adherence were the most important factors dete

90 th them, and might help to improve long-term treatment adherence when symptoms cannot be alleviated e

91 timely initiation of ART, and high levels of treatment adherence with viral load suppression.

92 of symptoms, difficulties with eating food, treatment adherence, worry about symptoms and illness, f